Primary infection cohort FRESH-PEF60076-en Asma ESSAT Primary infection cohort ANRS CO6 PRIMO FRESH-PEF60076-en 60076 FRESH-PEF60076 Cécile GOUJARD Asma ESSAT Laurence MEYER AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) null Cécile;GOUJARD Laurence;MEYER Heath events serious pathologies lipodystrophies death Infectious disease medicine Human immunodeficiency virus disease without mention of tuberculosis or malaria Socio-demographic and economic determinants Environmental determinants: Other Behavioral determinants Healthcare system determinants: Use of care Environmental determinants Healthcare system determinants Follow up of patients infected by HIV-1 for less than three months. 1. Improve the pathophysiological l knowledge of primary HIV infection - Study of the immune mechanisms involved early after infection - Kinetics of viral replication and establishment of cellular reservoirs at an early stage - Relationships between virological markers and immune response kinetics - Impact of resistance mutations, subtype and tropism on the disease progression and the response to treatment - Study of sub-groups of specific patients followed since primary infection, spontaneous or post treatment controllers, subjects with particular HLA 2. Assessing the impact of early, transient or prolonged treatment versus deferred treatment on the long-term prognosis of patients followed since primary infection, in terms of activation / inflammation and decrease in viral reservoirs 3. Contribute to knowledge in the epidemiology of HIV infection: - Modes of transmission - Sexual behavior before and after HIV diagnosis - Calendar trend of transmitted viral strains diversity (ARV resistance and subtypes) - Calendar trend of marker levels measured at primary infection 4. Contribute to national recommendations for therapeutic care, evaluate their implementation 5. Use observational data from the cohort for the development of therapeutic clinical trials in primary infection null France Individuals Patients population Male Female Other Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) 1) symptomatic or asymptomatic HIV-1 primary infection. 2) Infection date based on one of the following criteria: incomplete Western Blot; or positive p24 antigenemia/detectable plasma HIV RNA along with a negative or weakly positive ELISA or a negative or undetermined Western Blot, or a negative ELISA within the three previous months. 3) Enrollment within a maximum of 3 months after the estimated infection date. 4) Naive of antiretroviral treatment except for transient treatment taken in the context of PMTCT, PrEP or PEP. Clinical data Participant-reported health data Biological data Health event/morbidity Health event/mortality Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study Cohort study 1625 in January 2013 Unknown Restricted access data available to academic teams Access on specific project only